Pivmecillinam
Pivmecillinam is a beta-lactam antibiotic belonging to the penicillin group, used primarily to treat uncomplicated urinary tract infections (UTIs), particularly acute cystitis caused by susceptible bacteria such as Escherichia coli. It is a prodrug converted into mecillinam, which inhibits bacterial cell-wall synthesis by selectively binding to penicillin-binding protein 2 (PBP2), leading to bacterial cell death. Pivmecillinam is available as oral tablets, with treatment duration and dosage determined by the infection and local clinical guidelines. Common side effects include nausea, diarrhoea, abdominal discomfort, and vaginal yeast infections. Important precautions include penicillin allergy, gastrointestinal complications, and potential carnitine depletion with prolonged or repeated use. It should be used under medical supervision, with appropriate assessment of infection severity, kidney function, and antibiotic susceptibility.
Pivmecillinam was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Pivmecillinam, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Pivmecillinam from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Pivmecillinam, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
